# A5418 MPX-TPOXX Study Supplement

> **NIH NIH UM1** · UNIVERSITY OF CALIFORNIA LOS ANGELES · 2022 · $17,327,975

## Abstract

Abstract
This supplement will support A5418.
A5418 is Phase 3, randomized, placebo-controlled, double-blind trial of tecovirimat for the treatment of human
monkeypox virus (HMPXV). The study will also include a cohort of people who will receive open-label
tecovirimat including people with protocol-defined severe HMPXV, pregnant and breastfeeding individuals,
individuals less than 18 years of age, people with severe immune suppression or skin conditions placing them
at higher risk for severe disease.
The primary endpoint is the time to clinical resolution defined as all skin lesions are either scabbed,
desquamated or healed and all visible mucosal lesions healed.

## Key facts

- **NIH application ID:** 10688986
- **Project number:** 3UM1AI068636-16S4
- **Recipient organization:** UNIVERSITY OF CALIFORNIA LOS ANGELES
- **Principal Investigator:** Judith S. Currier
- **Activity code:** UM1 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $17,327,975
- **Award type:** 3
- **Project period:** 2006-06-29 → 2027-11-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10688986

## Citation

> US National Institutes of Health, RePORTER application 10688986, A5418 MPX-TPOXX Study Supplement (3UM1AI068636-16S4). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10688986. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*